Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:brand |
gptkb:Foradil
|
| gptkbp:class |
long-acting beta-agonist
|
| gptkbp:clinical_trial |
Phase III
prevent exercise-induced bronchospasm maintenance treatment |
| gptkbp:contraindication |
cardiac arrhythmias
hypersensitivity to formoterol severe asthma exacerbation |
| gptkbp:dosage_form |
inhalation powder
12 mcg |
| gptkbp:effective_date |
gptkb:2001
prescription only |
| gptkbp:excretion |
urine
|
| gptkbp:form |
aerosol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Foradil Aerolizer
|
| gptkbp:ingredients |
gptkb:formoterol
|
| gptkbp:interacts_with |
MAO inhibitors
diuretics beta-blockers tricyclic antidepressants |
| gptkbp:is_atype_of |
R03 A C13
|
| gptkbp:is_used_for |
gptkb:asthma
chronic obstructive pulmonary disease |
| gptkbp:manager |
inhalation
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:packaging |
gptkb:superhero
|
| gptkbp:pharmacokinetics |
rapid onset of action
long duration of action |
| gptkbp:population |
adults
children over 5 years |
| gptkbp:previous_name |
gptkb:formoterol_fumarate
|
| gptkbp:provides_information_on |
GINA guidelines
NHLBI guidelines |
| gptkbp:research |
post-marketing surveillance
ongoing clinical trials |
| gptkbp:safety_features |
lung function tests
monitoring for side effects regular follow-up visits |
| gptkbp:scholarships |
not for acute asthma attacks
not to exceed prescribed dose use with caution in patients with cardiovascular disease |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
dizziness
headache nervousness palpitations tremor |
| gptkbp:social_structure |
C21 H29 N1 O4 S
|
| gptkbp:storage |
room temperature
|
| gptkbp:bfsParent |
gptkb:formoterol
gptkb:formoterol_fumarate |
| gptkbp:bfsLayer |
5
|